1030017-70-9 Usage
Description
Imidazo[1,2-a]pyrimidine-7-carboxylic acid, 5-methylis an organic heterocyclic compound characterized by the presence of both an imidazole and a pyrimidine ring in its structure. The "5-methyl-" prefix signifies a methyl group attached to the fifth carbon of the pyrimidine ring. Imidazo[1,2-a]pyrimidine-7-carboxylic acid, 5-methylholds promise in medicinal chemistry and drug discovery due to its potential biological activity and utility as a building block for synthesizing pharmaceutical compounds.
Uses
Used in Medicinal Chemistry:
Imidazo[1,2-a]pyrimidine-7-carboxylic acid, 5-methylis utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Drug Discovery:
Imidazo[1,2-a]pyrimidine-7-carboxylic acid, 5-methylserves as a valuable scaffold in drug discovery, where it can be modified and optimized to enhance its biological activity. Its exploration can lead to the identification of novel therapeutic agents with improved efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 1030017-70-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,0,0,1 and 7 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1030017-70:
(9*1)+(8*0)+(7*3)+(6*0)+(5*0)+(4*1)+(3*7)+(2*7)+(1*0)=69
69 % 10 = 9
So 1030017-70-9 is a valid CAS Registry Number.
1030017-70-9Relevant articles and documents
HETEROBICYCLIC METALLOPROTEASE INHIBITORS
-
Page/Page column 136, (2008/12/05)
The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.
